WCC Biomedical today announced a major milestone: the company’s Investigational New Drug (IND) application for WCC-301, a combined Phase 1/2 clinical trial, has passed FDA
WCC Biomedical recently took part in the PharmaEd Microneedle and Intradermal Delivery Forum, a leading international gathering that brought together pharmaceutical companies, CDMOs, and academic
Microarray patches (MAPs) have promised painless, needle-free drug delivery for nearly three decades. The hard part was never the science — it was making the
June 6–7, 2026 | Kaohsiung Medical University Chung-Ho Memorial Hospital WCC Biomedical marked a significant milestone this June by participating in the Annual Conference of
WCC recently participated in the Taiwan Urologist Association (TUA) gathering at Kuang Tien General Hospital, an event bringing together renowned urologists and industry experts from
WCC Biomedical announced an remarkable achievement as its next-generation pain-relief product WCC-301 successfully completed the US FDA Pre-IND meeting and has now entered GLP toxicology studies,